Biohub, the research organization funded by the Chan Zuckerberg Initiative, announced Thursday that it will launch a new round of grants for the rare disease community this fall.
The initiative marks the fourth such funding cycle through its Rare As One Network, reinforcing the foundation's long-term commitment to addressing underserved medical conditions.
1 billion in funding to advance its AI drug design platform.
In parallel, Biohub is expanding its collaboration with Every Cure, a partnership focused on leveraging artificial intelligence for drug repurposing.
The move underscores a broader industry trend where AI-driven discovery platforms are becoming central to pharmaceutical R&D strategies, aiming to accelerate the identification of new therapeutic uses for existing compounds.
This development arrives amid a surge in private capital flowing into AI-enabled biotech.
Isomorphic Labs, a DeepMind spinout, recently secured $2.1 billion in funding to advance its AI drug design platform.